Background and objective: Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. Methods: We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. Key findings and limitations: Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. Conclusions and clinical implications: Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current "one-size-fits-all" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications / Aydogdu, C., Bukavina, L., Cheng, L., Al-Ahmadie, H.A., Alhalabi, O., Brown, J.R., Lopez-Beltran, A., Grivas, P., Hwang, C., Grass, G.D., Kamat, A.M., Chatzkel, J., Mian, O., Necchi, A., Ross, J., Apolo, A.B., Spiess, P.E., Li, R.. - In: EUROPEAN UROLOGY. - ISSN 1873-7560. - (2026). [10.1016/j.eururo.2026.05.030]

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications

Necchi, Andrea;
2026-01-01

Abstract

Background and objective: Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. Methods: We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. Key findings and limitations: Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. Conclusions and clinical implications: Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current "one-size-fits-all" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.
2026
Inglese
Pubblicato
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
Divergent differentiation
Histologic subtypes
Molecular genomics
Neoadjuvant chemotherapy
Radical cystectomy
Systemic therapy
Urothelial carcinoma
Variant histology
Sì
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications / Aydogdu, C., Bukavina, L., Cheng, L., Al-Ahmadie, H.A., Alhalabi, O., Brown, J.R., Lopez-Beltran, A., Grivas, P., Hwang, C., Grass, G.D., Kamat, A.M., Chatzkel, J., Mian, O., Necchi, A., Ross, J., Apolo, A.B., Spiess, P.E., Li, R.. - In: EUROPEAN UROLOGY. - ISSN 1873-7560. - (2026). [10.1016/j.eururo.2026.05.030]
none
18
info:eu-repo/semantics/article
262
Aydogdu, Can; Bukavina, Laura; Cheng, Liang; Al-Ahmadie, Hikmat A; Alhalabi, Omar; Brown, Jason R; Lopez-Beltran, Antonio; Grivas, Petros; Hwang, Clar...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/207989
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact